Investigation of the Pathophysiology of Pancreatic and Brain Tumors Using Carbon-11-Labeled Methyl-Leucine PET

Investigation of the Pathophysiology of Pancreatic and Brain Tumors Using Carbon-11-Labeled Methyl-Leucine PET - Investigation of the Pathophysiology of Pancreatic and Brain Tumors Using Carbon-11-Labeled Methyl-Leucine PET

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000061097

Enrollment

500

Registered

2026-03-29

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic and brain tumors

Interventions

Carbon-11-labeled methyl-leucine will be intravenously administered at a dose of 5-10 MBq/kg and PET/CT imaging of the lesion will be performed for 20 minutes between 15 and 60 minutes after injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with pancreatic or brain tumors or suspected tumors

Exclusion criteria

Exclusion criteria: Participants meeting any of the following criteria will be excluded: Patients who are pregnant or may be pregnant Patients with an urgent and life-threatening condition Patients deemed unsuitable for the study by the investigator

Design outcomes

Primary

Measure	Time frame
carbon-11-labeled methyl-leucine uptake quantified as the standardized uptake value	—

Countries

Japan

Contacts

Public ContactYuka yamamoto

Faculty of Medicine, Kagawa University Radiology

yamamoto.yuka@kagawa-u.ac.jp087-898-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026